血清脑源性tau与重型创伤性脑损伤患者临床结局及纵向变化的关系
这项在瑞典萨尔格伦斯卡大学医院神经重症监护室开展的前瞻性队列研究纳入39例重型创伤性脑损伤患者,于伤后第0、7、365天检测血清脑源性tau、总tau、磷酸化tau231和神经丝轻链。第0天脑源性tau在不良结局组(GOS 1-3)高于良好结局组(GOS 4-5),平均差115.9 pg/mL(95%CI 25.7-206.1 pg/mL),其他标志物组间平均差较小且置信区间跨0。纵向随访中脑源性tau下降慢于总tau和磷酸化tau231,神经丝轻链则先升后降。作者认为血清脑源性tau可作为监测重型创伤性脑损伤结局的生物标志物,并提供急性神经元损伤的信息。
要点
- 重型创伤性脑损伤患者第0天血清脑源性tau在不良结局组(GOS 1-3)为191.4(190.8)pg/mL,高于良好结局组(GOS 4-5)的75.6(60.3)pg/mL,平均差115.9 pg/mL(95%CI 25.7-206.1 pg/mL)。
- 第7天结果与第0天相似;总tau、磷酸化tau231和神经丝轻链的组间平均差较小且95%CI均跨0(总tau 60.3 pg/mL,95%CI -22.0至142.7;磷酸化tau231 8.3 pg/mL,95%CI -6.4至23.0;神经丝轻链 -5.4 pg/mL,95%CI -99.0至88.3)。
- 纵向随访中脑源性tau下降较慢:第7天下降42.2%(从138.6降至80.1 pg/mL),第365天下降93.0%(从138.6降至9.7 pg/mL),而总tau第7天下降81.5%、第365天下降99.0%,磷酸化tau231第7天下降92.5%、第365天下降95.0%。
- 神经丝轻链轨迹不同:第7天较第0天升高255.9%(从86.8升至308.9 pg/mL),第365天较第7天下降97.0%(从308.9降至9.2 pg/mL)。
适用人群与场景
- 瑞典哥德堡萨尔格伦斯卡大学医院神经重症监护室收治的重型创伤性脑损伤患者,2006年9月1日至2015年7月1日纳入,共39例,随访至1年。
诊断标准与关键阈值
- 采用格拉斯哥昏迷评分在入院时评估重型创伤性脑损伤严重程度。
- 采用格拉斯哥结局量表在1年随访时评估临床结局,GOS评分4-5分为良好结局,GOS评分1-3分为不良结局。
研究设计与关键结果
- 研究类型为前瞻性队列研究,纳入39例重型创伤性脑损伤患者(入院中位年龄36岁,IQR 22-54岁;男性26例,66.7%),在伤后第0、7、365天检测血清脑源性tau、总tau、磷酸化tau231和神经丝轻链。
- 第0天血清脑源性tau不良结局组为191.4(190.8)pg/mL,良好结局组为75.6(60.3)pg/mL,平均差115.9 pg/mL(95%CI 25.7-206.1 pg/mL)。
- 第0天其他标志物组间平均差:总tau 60.3 pg/mL(95%CI -22.0至142.7 pg/mL);磷酸化tau231 8.3 pg/mL(95%CI -6.4至23.0 pg/mL);神经丝轻链 -5.4 pg/mL(95%CI -99.0至88.3 pg/mL)。
- 第7天记录到与第0天相似的结果。
- 全队列纵向变化:脑源性tau第7天下降42.2%(从138.6降至80.1 pg/mL),第365天下降93.0%(从138.6降至9.7 pg/mL);总tau第7天下降81.5%(从57.3降至10.6 pg/mL),第365天下降99.0%(从57.3降至0.6 pg/mL);磷酸化tau231第7天下降92.5%(从20.1降至1.5 pg/mL),第365天下降95.0%(从20.1降至1.0 pg/mL)。
- 考虑临床结局后上述结果不变,两组中总tau下降速度均为脑源性tau的两倍,磷酸化tau231得到相似结果。
- 第365天脑源性tau水平低于第7天,而总tau和磷酸化tau231未显示此差异。
- 神经丝轻链轨迹不同:第7天较第0天升高255.9%(从86.8升至308.9 pg/mL),第365天较第7天下降97.0%(从308.9降至9.2 pg/mL)。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 作者结论:本研究提示血清脑源性tau、总tau和磷酸化tau231与重型创伤性脑损伤患者临床结局及1年纵向变化存在不同关联;血清脑源性tau显示作为监测重型创伤性脑损伤结局的生物标志物的效用,并可提供关于急性神经元损伤的有价值信息。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,血清脑源性tau可作为监测重型创伤性脑损伤结局的生物标志物,并可提供关于急性神经元损伤的信息。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Blood-based measurements of total tau (T-tau) are commonly used to examine neuronal injury in patients with traumatic brain injury (TBI), but current assays do not differentiate between brain-derived tau (BD-tau) and tau produced in peripheral tissues. A novel assay for BD-tau has recently been reported that selectively quantifies nonphosphorylated tau of central nervous system origin in blood samples.
OBJECTIVES: To examine the association of serum BD-tau with clinical outcomes in patients with severe TBI (sTBI) and its longitudinal changes over 1 year.
DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was conducted at the neurointensive unit at the Sahlgrenska University Hospital, Gothenburg, Sweden, between September 1, 2006, and July 1, 2015. The study included 39 patients with sTBI followed up for up to 1 year. Statistical analysis was performed between October and November 2021.
EXPOSURES: Serum BD-tau, T-tau, phosphorylated tau231 (p-tau231), and neurofilament light chain (NfL) measured on days 0, 7, and 365 after injury.
MAIN OUTCOMES AND MEASURES: Associations of serum biomarkers with clinical outcome and longitudinal change in sTBI. Severity of sTBI was evaluated using the Glasgow Coma Scale at hospital admission, while clinical outcome was assessed with the Glasgow Outcome Scale (GOS) at 1-year follow-up. Participants were classified as having a favorable outcome (GOS score, 4-5) or unfavorable outcome (GOS score, 1-3).
RESULTS: Among the 39 patients (median age at admission, 36 years [IQR, 22-54 years]; 26 men [66.7%]) in the study on day 0, the mean (SD) serum BD-tau level was higher among patients with unfavorable outcomes vs those with favorable outcomes (191.4 [190.8] pg/mL vs 75.6 [60.3] pg/mL; mean difference, 115.9 pg/mL [95% CI, 25.7-206.1 pg/mL]), while the other markers had smaller between-group mean differences (serum T-tau, 60.3 pg/mL [95% CI, -22.0 to 142.7 pg/mL]; serum p-tau231, 8.3 pg/mL [95% CI, -6.4 to 23.0 pg/mL]; serum NfL, -5.4 pg/mL [95% CI, -99.0 to 88.3 pg/mL]). Similar results were recorded on day 7. Longitudinally, baseline serum BD-tau concentrations showed slower decreases in the whole cohort (42.2% on day 7 [from 138.6 to 80.1 pg/mL] and 93.0% on day 365 [from 138.6 to 9.7 pg/mL]) compared with serum T-tau (81.5% on day 7 [from 57.3 to 10.6 pg/mL] and 99.0% on day 365 [from 57.3 to 0.6 pg/mL]) and p-tau231 (92.5% on day 7 [from 20.1 to 1.5 pg/mL] and 95.0% on day 365 [from 20.1 to 1.0 pg/mL]). These results did not change when considering clinical outcome, where T-tau decreased twice as fast as BD-tau in both groups. Similar results were obtained for p-tau231. Furthermore, the biomarker levels on day 365 were lower, compared with day 7, for BD-tau but not T-tau or p-tau231. Serum NfL had a different trajectory to the tau biomarkers, with levels increasing by 255.9% on day 7 compared with day 0 (from 86.8 to 308.9 pg/mL) but decreasing by 97.0% by day 365 vs day 7 (from 308.9 to 9.2 pg/mL).
CONCLUSIONS AND RELEVANCE: This study suggests that serum BD-tau, T-tau, and p-tau231 have differential associations with clinical outcome and 1-year longitudinal change in patients with sTBI. Serum BD-tau demonstrated utility as a biomarker to monitor outcomes in sTBI and can provide valuable information regarding acute neuronal damage.
参考来源
- Gonzalez-Ortiz F, Dulewicz M, Ashton NJ, et al. Association of Serum Brain-Derived Tau With Clinical Outcome and Longitudinal Change in Patients With Severe Traumatic Brain Injury. JAMA Netw Open. 2023. PMID: 37399012. doi:10.1001/jamanetworkopen.2023.21554
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。